PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

TY - JOUR

T1 - PARADIGM study

T2 - A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

AU - Muro, K.

AU - Uetake, H.

AU - Tsuchihara, K.

AU - Shitara, K.

AU - Yamazaki, K.

AU - Ota, M.

AU - Oki, E.

AU - Sato, T.

AU - Naitoh, T.

AU - Komatsu, Y.

AU - Kato, T.

AU - Yamanaka, K.

AU - Mori, I.

AU - Soeda, J.

AU - Hihara, M.

AU - Yamanaka, T.

AU - Akagi, K.

AU - Ochiai, A.

AU - Yoshino, T.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85079794788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079794788&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz155.033

DO - 10.1093/annonc/mdz155.033

M3 - Article

C2 - 32084926

SN - 0923-7534

VL - 30

SP - iv10

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -